본문 바로가기

Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION22(8) · pp.1455 · 2016
피인용
Web of Science 18
JCR IF
JCR 2015 3.98
ISSN
1083-8791

저자

  1. Kang, Hyoung Jin제1저자Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
  2. Hong, Kyung TaekDepartment of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
  3. Lee, Ji WonDepartment of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
  4. Kim, HyeryDepartment of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
  5. Park, Kyung DukDepartment of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
  6. Shin, Hee YoungDepartment of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
  7. Lee, Soo HyunDepartment of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
  8. Yoo, Keon HeeDepartment of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
  9. Sung, Ki WoongDepartment of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
  10. Koo, Hong HoeDepartment of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
  11. Lee, Jae WookDepartment of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, South Korea
  12. Chung, Nak GyunDepartment of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, South Korea
  13. Cho, BinDepartment of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, South Korea
  14. Kim, Hack KiDepartment of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, South Korea
  15. Koh, Kyung NamDepartment of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
  16. Im, Ho JoonDepartment of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
  17. Seo, Jong JinDepartment of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
  18. Jung, Hyun JooDepartment of Pediatrics, Ajou University School of Medicine, Suwon, South Korea
  19. Park, Jun EunDepartment of Pediatrics, Ajou University School of Medicine, Suwon, South Korea
  20. Lee, Young HoDepartment of Pediatrics, Hanyang University College of Medicine, Seoul, South Korea
  21. 임영탁Department of Pediatrics, Pusan National University School of Medicine, Pusan, South Korea
  22. Lim, Yeon JungDepartment of Pediatrics, Chungnam National University College of Medicine, Daejeon, South Korea
  23. Kim, Sun YoungDepartment of Pediatrics, Chungnam National University College of Medicine, Daejeon, South Korea
  24. Yoo, Eun SunDepartment of Pediatrics, Ewha Woman's University School of Medicine, Seoul, South Korea
  25. Ryu, Kyung HaDepartment of Pediatrics, Ewha Woman's University School of Medicine, Seoul, South Korea
  26. Lee, Jae HeeDepartment of Pediatrics, Chung-Ang University Hospital, Seoul, South Korea
  27. Park, Jeong-ADepartment of Pediatrics, Inje University Haeundae Paik Hospital, Pusan, South Korea
  28. Park, Sang KyuDepartment of Pediatrics, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea
  29. Ahn, Hyo Seop교신저자Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea

초록

Hematopoietic stem cell transplantation (HSCT) is a curative therapy for severe aplastic anemia (SAA); however, the optimal conditioning regimen for HSCT with an unrelated donor has not yet been defined. A previous study using a fludarabine (FLU), cyclophosphamide (Cy), and antithymocyte globulin (ATG) conditioning regimen (study A: 50 mg/kg Cy once daily i.v. on days -9, -8, -7, and -6; 30 mg/m(2) FLU once daily i.v. on days -5, -4, -3, and -2; and 2.5 mg/kg of ATG once daily i.v. on days -3, -2, and -1) demonstrated successful engraftment (100%) but had a high treatment-related mortality rate (32.1%). Therefore, given that Cy is more toxic than FLU, we performed a new phase II prospective study with a reduced-toxicity regimen (study B: 60 mg/kg Cy once daily i.v. on days -8 and -7; 40 mg/m(2) FLU once daily i.v. on days -6, -5, -4, -3, and -2; and 2.5 mg/kg ATG once daily i.v. on 3 days). Fifty-seven patients were enrolled in studies A (n = 28) and B (n = 29), and donor type hematologic recovery was achieved in all patients in both studies. The overall survival (OS) and event-free survival (EFS) rates of patients in study B was markedly improved compared with those in study A (OS: 96.7% versus 67.9%, respectively, P =.004; EFS: 93.3% versus 64.3%, respectively, P =.008). These data show that a reduced-toxicity conditioning regimen with FLU, Cy, and ATG may be an optimal regimen for SAA patients receiving unrelated donor HSCT. (C) 2016 American Society for Blood and Marrow Transplantation.

키워드

Severe aplastic anemiaUnrelated donorFludarabineCyclophosphamideThymoglobulinAntithymocyte globulin (ATG)STEM-CELL TRANSPLANTATIONVERSUS-HOST-DISEASEMARROW TRANSPLANTATIONIMMUNOSUPPRESSIVE THERAPYCHILDRENFAILURETHYMOGLOBULINIRRADIATIONATG

식별자

WoS UID
000380417400017